Off-Trial Evaluation of the B cell-Targeting Treatment in the Refractory Cases of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: Long-Term Follow-Up from a Single Centre

Scandinavian Journal of Immunology

Volumn 76, Issue 4, 2012, Pages 411-420

  Pullerits, R ^a   Ljevak, M ^a   Vikgren, J ^a   Bokarewa, M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE EXACERBATION; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT DISEASE; RETREATMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS SCORE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; DRUG THERAPY, COMBINATION; EYE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MIDDLE AGED; REMISSION INDUCTION; RESEARCH DESIGN; RESPIRATORY SYSTEM; SEVERITY OF ILLNESS INDEX;

EID: 84866265575     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02747.x     Document Type: Article

References (28)

1. Gaskin G, Savage CO, Ryan JJ et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991;6:689-94.
2. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
3. Sneller MC. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum 2005;52:1-5.
4. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999;103:885-94.
5. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958;2:265-70.
6. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
7. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
8. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92.
9. Wong CF. Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol Dial Transplant 2007;22:32-6.
10. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
11. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
12. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
13. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
14. Bloch DA, Michel BA, Hunder GG et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum 1990;33:1068-73.
15. Stone JH, Hoffman GS, Merkel PA et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912-20.
16. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35:826-33.
17. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004-10.
18. Avshovich N, Boulman N, Slobodin G, Zeina AR, Rosner I, Rozenbaum M. Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement. Isr Med Assoc J 2009;11:566-8.
19. Ooka S, Maeda A, Ito H, Omata M, Yamada H, Ozaki S. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report. Mod Rheumatol 2009;19:80-3.
20. Tamura N, Matsudaira R, Hirashima M et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007;46:409-14.
21. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009;60:1540-7.
22. Martinez DelPero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009;34:328-35.
23. Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-8.
24. Kowalewska B, Szechinski J, Roszkowska E. Wegener's granulomatosis effectively treated with rituximab: a case study. Pol Arch Med Wewn 2008;118:381-5.
25. Oristrell J, Bejarano G, Jordana R et al. Effectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature. Open Respir Med J 2009;3:94-9.
26. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-18.
27. Hinze CH, Colbert RA. B-cell depletion in Wegener's granulomatosis. Clin Rev Allergy Immunol 2008;34:372-9.
28. Guerry MJ, Brogan P, Bruce IN et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2012;51:634-43.